STAT Plus: Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers
Four years after it was founded, Kymera Therapeutics said Thursday that it has now raised more than a quarter-billion dollars from investors keen on its potential approach to treat a range of diseases, including blood cancers.
The Cambridge, Mass., biotech shared the total after announcing that it had closed a third round of venture capital fundraising that totaled $102 million.The privately held startup plans to begin clinical trials of at least three drugs by next year.
